MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway
Saiqun Zhang(Soochow University), Zeyi Liu(Soochow University), Jian Zhao(Liaoning Cancer Hospital & Institute), Mengzhu Zhang(Hohai University), Jianjie Zhu(Soochow University), Yuanyuan Zeng(Sichuan University), Anqi Wang(Soochow University), Chang Li(University of Washington Medical Center), Jianjun Li(Qingdao University), Yuling Chen(Center for Life Sciences), Min Jiao, Chuanyong Mu(Soochow University), Chenkang Ma(Soochow University), Jian-An Huang(Soochow University)
Cited by 3
Related Papers
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
|International Journal of Oncology|2016|385
Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer
|Molecular Cancer|2018|369
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
|International Journal of Clinical Oncology|2017|315
JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells
|International Journal of Oncology|2014|314